Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onalespib + Paclitaxel in Advanced TNBC
NCT02474173Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2016
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of onalespib in triple-negative breast cancer (TNBC), sponsored by National Cancer Institute. Primary endpoints: Recommended Phase 2 Dose at 28 days and Toxicity Profile based on CTCAE v5.0 at 2 years. Started Jan 2016; status: terminated.
02
Drugs
onalespib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02474173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02474173.